A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment

BACKGROUND: Human epidermal growth factor 2 (HER2) is an effective therapeutic target in breast cancer; however, resistance to anti-HER2 agents such as trastuzumab and lapatinib develops. In a preclinical model, an HDAC inhibitor epigenetically reversed the resistance of cancer cells to trastuzumab...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Br J Cancer
Glavni autori: Lim, Bora, Murthy, Rashmi K., Lee, Jangsoon, Jackson, Summer A., Iwase, Toshiaki, Davis, Darren W., Willey, Jie S., Wu, Jimin, Shen, Yu, Tripathy, Debu, Alvarez, Ricardo, Ibrahim, Nuhad K., Brewster, Abenaa M., Barcenas, Carlos H., Brown, Powel H., Giordano, Sharon H., Moulder, Stacy L., Booser, Daniel J., Moscow, Jeffrey A., Piekarz, Richard, Valero, Vicente, Ueno, Naoto T.
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2019
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6738035/
https://ncbi.nlm.nih.gov/pubmed/31097774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0473-y
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items